CN102319266B - 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物 - Google Patents

用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物 Download PDF

Info

Publication number
CN102319266B
CN102319266B CN201110219831.4A CN201110219831A CN102319266B CN 102319266 B CN102319266 B CN 102319266B CN 201110219831 A CN201110219831 A CN 201110219831A CN 102319266 B CN102319266 B CN 102319266B
Authority
CN
China
Prior art keywords
acid
purposes
oil extract
krill oil
triglyceride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN201110219831.4A
Other languages
English (en)
Other versions
CN102319266A (zh
Inventor
蒂娜·桑帕利什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neptune Technologies and Bioressources Inc
Original Assignee
Neptune Technologies and Bioressources Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23150259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102319266(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neptune Technologies and Bioressources Inc filed Critical Neptune Technologies and Bioressources Inc
Publication of CN102319266A publication Critical patent/CN102319266A/zh
Application granted granted Critical
Publication of CN102319266B publication Critical patent/CN102319266B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/612Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

本发明涉及一种治疗和/或预防心血管疾病、风湿性关节炎、皮肤癌、经前综合症、糖尿病和透皮转运增强的方法。所述方法包括给患者施用治疗有效量的磷虾和/或海产油。本发明还涉及用于治疗和/或预防这些疾病的组合物。

Description

用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
本专利申请是中国专利申请CN 02812181.3(对应于PCT国际申请PCT/CA02/00843)的分案申请。 
发明背景
发明领域
本发明涉及来自磷虾和/或海产的多治疗提取物,它可以预防和/或治疗疾病。 
现有技术描述
磷虾是小形、虾状甲壳动物的通用名称,但不是虾,它群集在稠密的浅滩,特别是在南极水域中。它是一种最重要的鱼类,某些鸟类的食物来源,特别是须鲸类的重要的蛋白质来源。磷虾还是熟知的有益健康的ω-3脂肪酸的良好来源。 
本领域中已知使用磷虾和/或海产酶治疗多种人和动物疾病如感染、炎症、癌、HIV/AIDS、疼痛、息肉、疣、痔、空斑、皱纹、头发稀少、过敏性痒病、抗粘着、眼病、痤疮、胆囊纤维变性和免疫疾病,包括自体免疫疾病和癌症。 
在本领域中也已知磷虾和/或海产油可以用于治疗自体免疫性鼠型狼疮和其它自体免疫疾病,并还可以用于治疗心血管疾病。 
但是,用于这些治疗的磷虾和/或海产油仅保存其ω-3脂肪酸作为活性成分,它是磷虾和/或海产本身的所有活性成分的一个非常小的部分。这个事实降低了磷虾和/或海产油作为这些疾病的治疗剂的可能性。 
使用来自天然产物的需求日益增加,因此非常期望提供具有增大的预防和/或治疗和/或控制疾病的可能性的磷虾和/海产提取物。 
发明概述
本发明提供一种预防、治疗(therapy)和/或治疗(treatment)多种疾病的方法,所述方法包括给患者施用药学上有效量的磷虾和/或海产油。 
在本发明的一个优选的实施方案中,所述磷虾和/或海产油由包括以下步骤的方法得到: 
a)将磷虾和/或海产材料放置在酮溶剂,优选丙酮中,以实现从该海产和/或水生动物材料中提取可溶的脂质部分; 
b)分离液体和固体内容物; 
c)通过蒸发液体内容物中存在的溶剂而从液体内容物中回收第一富含脂质的部分; 
d)将该固体内容物放置在选自以下的有机溶剂中:醇,优选乙醇、异丙醇或叔丁醇和乙酸酯,优选乙酸乙酯,以实现从该海产和/或水生材料中提取剩余的可溶性脂质部分; 
e)分离液体和固体内容物; 
f)通过从液体内容物中蒸发溶剂而回收第二富含脂质的部分;和 
g)回收固体内容物。 
在本发明的一个优选的实施方案中,所述磷虾和/或海产油包含二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。 
在本发明的另一个实施方案中,所述磷虾和/或海产油包含二十碳五烯酸、二十二碳六烯酸、亚麻酸、α-亚麻酸、亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、神经酸、磷脂酰胆碱、磷脂酰肌 醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、胆固醇、甘油三酸酯、甘油一酸酯、α-生育酚、全反式视黄醇、虾青素、斑蝥黄、β-胡萝卜素、类黄酮、锌、硒、钠、钾和钙。 
在本发明的另一个实施方案中,所述磷虾和/或海产油包含二十碳五烯酸、二十二碳六烯酸、亚麻酸、α-亚麻酸、亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、胆固醇、甘油三酸酯、甘油一酸酯、α-生育酚、全反式视黄醇、虾青素、斑蝥黄、β-胡萝卜素、锌和硒。 
可以用本发明的方法治疗和/或预防的疾病为心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运增强。 
本发明还提供一种用于治疗(treatment)和/或预防和/或治疗(therapy)前述疾病的组合物,所述组合物包含治疗有效量的磷虾和/或海产油和药学上可接受的载体。 
本发明还提供磷虾和/或海产油用于治疗(treatment)和/或预防和/或治疗(therapy)前述疾病的用途。 
本发明还提供磷虾和/或海产油用于制备治疗(treatment)和/或预防和/或治疗(therapy)前述疾病的药物的用途 
发明详述 
本发明提供用于预防和/或治疗(treatment)和/或治疗(therapy)多种疾病的磷虾和/海产提取物。 
不含酶的多治疗油来自磷虾和/或海产,发现于全世界任何海洋环境,例如南极海洋(南极磷虾)、太平洋(太平洋磷虾)、大西洋、印度洋,特别是毛里求斯岛和/或马达加斯加群岛、加拿大西部海岸、日本海岸、 圣-劳伦斯海湾和Fundy海湾的沿海地区,且这种油提取物是一种游离脂肪酸脂质部分。 
提取方法可以描述如下: 
a)将海产和/或水生磷虾和/或海产放置在酮溶剂,优选丙酮中,以实现对磷虾和/或海产脂肪的提取; 
b)分离液体内容物和固体内容物; 
(c)通过蒸发液体内容物中存在的溶剂而回收在步骤(b)中得到的液体内容物的富含脂质的部分; 
(d)将固体内容物放置在有机溶剂,所述溶剂可以是醇,优选乙醇、异丙醇或叔丁醇或乙酸酯,优选乙酸乙酯。由此从固体内容物中提取剩余的可溶性脂质部分; 
(e)分离液体内容物和固体;和 
(f)通过蒸发在液体内容物中存在的溶剂而回收在步骤(e)中得到的液体内容物中的富含脂质的部分。 
不含酶的磷虾和/或海产油提取物的活性成分是: 
脂质 
i)ω-3: 
i.二十碳五烯酸:>8g/100g 
ii.二十二碳六烯酸:>2g/100g 
iii.亚麻酸:>0.10g/100g 
iv.(α-亚麻酸:>0.3g/100g 
在本发明的优选的实施方案中,发现ω-3多于30g/100g。 
ii)ω-6: 
i.亚油酸:>0.9g/100g 
ii.花生四烯酸:<0.45g/100g,优选<0.6g/100g 
iii)ω-9:i.油酸:>5g/100g 
iv)棕榈酸:>10g/100g 
v)棕榈油酸:0.08g/100g 
vi)硬脂酸:>0.5g/100g 
磷脂 
磷脂酰胆碱:>4.5g/100g 
磷脂酰肌醇:>107mg/100g 
磷脂酰丝氨酸:>75mg/100g 
磷脂酰乙醇胺:>0.5g/100g 
鞘磷脂:>107mg/100g 
中性脂质 
胆固醇:<3g/100g 
甘油三酸酯:<55g/100g 
甘油一酸酯:>0.5g/100g 
在本发明的另一个实施方案中,磷虾和/海产提取物的中性脂质还包含: 
甘油二酸酯:>0.5g/100g 
抗氧剂 
α-生育酚(维生素E):>1.0IU/100g 
全反式视黄醇(维生素A):>1500IU/100g 
β-胡萝卜素:>3000μg/100ml 
色素 
虾青素:>20mg/100g 
斑蝥黄:>2mg/100g 
金属 
锌:>0.1mg/100g 
硒:>0.1mg/100g 
在本发明的另一个实施方案中,磷虾和/海产提取物还包含: 
类黄酮:>0.5mg/100g 
钠:<500mg/100g 
钙:>0.1mg/100g 
钾:>50mg/100g 
铝:<8.5mg/100g 
蛋白质:>4g/100g 
水份和挥发性物质:<0.8% 
在表征磷虾和/或海产油提取物之后,测定提取物含有少于25ppm的来自提取方法的溶剂残留物。 
所述的油具有以下稳定性指数: 
过氧化物值:<0.1(mEq/kg) 
油稳定性指数:<97.8℃下50小时后为0.1 
皂化指数:70-180 
碘值:60-130% 
参照以下的实施例将更为容易地理解本发明,所述实施例以例示本发明而不是限定其范围的方式提供。 
实施例1
心血管疾病预防和/或治疗 
已表明磷虾和/或海产油降低体内胆固醇。它还抑制血小板粘附和斑块形成,并减少患者的血管内皮炎症。它可以预防高血压。它预防低密度脂蛋白的氧化。它可以具有抑制VLDL分泌的活性,因为它增加细胞内apo B-100降解。它还预防后心肌梗塞,因为它能够减少CIII载脂蛋白B,降低CIII非载脂蛋白B脂蛋白和提高抗凝血酶III水平。磷虾和/或海产油适于人心血管疾病的预防用途,其中心血管疾病涉及冠状动脉疾病、高脂血症、高血压、局部缺血疾病(涉及绞痛、心肌梗塞、脑局部缺血、无临床或实验室局部缺血症状的休克、心律失常)。 
为了评价磷虾和/或海产油对动脉硬化性冠状动脉疾病和高脂血症过程作用,对已知高脂血症患者进行研究(前瞻性临床试验,统计学显著性,p<0.05)。 
13名患者小组服用磷虾和/或海产油浓缩物胶囊。鱼油和磷虾和/或海产油包含等量的ω-3脂肪酸。建议的剂量为1-6个胶囊/天,每个胶囊包含800mg油。在此研究中,每名患者服用6个胶囊/天。 
测试患者治疗前和第2个月时的LDL、HDL、甘油三酸酯、生活症、CBC、SGOT/SGPT、γ-GT、ALP、尿素、肌酸、葡萄糖、K+、Na+、Ca2+与总间接胆红素胆固醇。 
表1显示由前述试验得到的结果。 
表1
成对样品试验 
根据上述表明日摄入1-4.8g磷虾提取物使患者的胆固醇降低的范围为15%,甘油三酸酯降低的范围为15%,HDL升高的范围为8%,LDL降低的范围为13%,而胆固醇/HDL比率降低14%。 
这表明摄入磷虾提取物对患有高脂血症的患者具有有益效果,而高脂血症已知是动脉粥样硬化主要诱因因素。 
实施例2
关节炎治疗 
磷虾和/或海产油症状缓解关节炎,其中关节炎涉及成人关节炎、斯提耳氏病、多关节或少关节少年风湿性关节炎、风湿性关节炎、骨关节炎,因为已表明它在临床上改善脆弱关节数量的减少和由于人患者白介素-8和白介素-1生产的减少而导致的每日服用止痛剂。具有出血倾向或严重精神病的患者从此研究中排除。 
为了评价磷虾和/或海产油补充剂对骨关节炎的临床过程的作用,对诊断并接受治疗的骨关节患者进行试验(前瞻性临床试验,统计学差异p<0.05),这些患者是活性I、II或III类,并在登记之前用NSAIDs和/或止痛剂治疗至少3个月。 
13名患者试验组以每日6个800mg磷虾油/胶囊的速率服用磷虾和/或海产油浓缩物胶囊。建议的剂量范围为1-4.8克纯磷虾提取物/天。要求患者遵循由20%脂肪(少于10%的动物脂肪)、40%的蛋白质和40%的糖类组成的正常的健康饮食。 
研究的纳入标准是年龄为50-65岁,两种性别可以接受,在研究登记前6-12个月临床诊断患有原发性骨关节炎(轻度至中度),包括疼痛和僵硬,放射照相证明登记前的疾病。它还包括在研究登记前有至少3个月的可测定的OA症状,要求使用对乙酰氨基酚、抗炎剂或阿片类止痛剂。为了洗脱目的,要求患者在开始试验前停止使用所有“疼痛-去除剂”排除标准为严重骨关节炎,不可避免持续使用NSAID′s、阿斯匹林或其它抗炎用药物,在4周随机观察中使用局部止痛剂,在过去的3个月内将类固醇注射到任一膝盖中,在3个月内开始理疗或肌肉调理,海鲜过敏,使用抗凝剂或水杨酸盐,每天超过3次混合饮酒的酒精消耗,可能混淆或干扰疼痛评价的并行的医疗/关节炎疾病,先前任一膝盖的手术(包括关节镜检查),已知的骨关节炎的“继发性” 原因。 
在日剂量的NSAIDs和/或止痛剂和/或SAARDs、疼痛关节数、膨胀关节数、晨痛持续时间、视觉模拟范围(0-100)WOMAC范围和SF36的基础上进行评价。2个月后得到初步的结果。已在试验开始时和开始后2个月记录每日起作用所需的NSAIDs和/或止痛剂和/或SAARDs的数量 
表2所示的结果表明磷虾提取物的摄入对关节炎缓解的作用。 
表2 
    频率%   %   有效%   蓄积%
  无变化   3   23.1   23.1   23.1
  疼痛缓解   10   76.9   76.9   100.0
  总数   13   100.0   100.0  
这表明13分之10(76.9%)的人报道疼痛缓解和大关节(下背部、膝盖、肩)灵活性的改善。 
实施例3
皮肤癌预防 
已表明磷虾和/或海产油预防皮肤癌,因为它的视黄醇抗致癌作用、虾青素抗致癌作用和它的磷脂抗致癌作用。 
为了评价磷虾和/或海产油抗UVB诱导的皮肤癌的光保护效力,对裸鼠,优选对C57BL6裸同类系小鼠-B6NU-T(杂合体)进行研究,因它们证明易患皮肤癌。 
形成的试验组如下:48鱼油:16口服(po)补充剂,16局部用途,16口服和局部用途;48磷虾和/或海产油:16口服,16局部用途,16口服和局部用途。为了实现磷虾和/或海产油预防皮肤癌的效力,进行 随机的盲对照试验(统计学差异p<0.05)。半数小鼠口服或局部使用或同时口服和局部使用含100wt%的磷虾和/或海产油进行治疗,而另一半以相同的方式用鱼油治疗。 
第一周的营养物是不含脂肪的食物,而在随后的2-20周相应地对下述的指定的试验组的营养物改为每日1ml数量的油。 
将小鼠分成如下6组: 
A组:不含脂肪的食物,补充鱼油(20%总卡路里) 
B组:不含脂肪的食物(100%卡路里)+局部用途鱼油2次/天 
C组:不含脂肪的食物,补充鱼油(20%的总卡路里)+局部用途大豆油2次/天 
D组:不含脂肪的食物,补充磷虾和/或海产油(20%的总卡路里) 
E组:不含脂肪的食物(100%的卡路里)+局部用途磷虾和/或海产油2次/天 
F组:不含脂肪的食物,补充磷虾和/或海产油(20%总卡路里)+局部用途磷虾和/或海产油2次/天 
已在2-20周期间使用荧光试验灯,发射光谱270-400nm使小鼠接受UVB照射。在每天30分钟UVB接触期间进行试验,并使试验灯处在距小鼠30cm的距离。在20周结束时或当恶性肿瘤形成时,用醚麻醉小鼠并将其处死。由病理学家屏蔽检查皮肤的致癌症状。 
下表(表3-8)显示在5周期间将紫外照射施用于小鼠皮肤时所得的关于癌症发生率的结果。 
表3
磷虾提取物口服 
表4
对照物口服 
表5
磷虾提取物局部摄入 
表6
对照物局部摄入 
表7
磷虾提取物的局部和口服摄入 
表8
对照物的局部和口服摄入 
所得的结果表明磷虾油的口服和局部使用都有效地保护皮肤抵抗UVB照射诱导的皮肤癌。 
实施例4
治疗用途中的透皮转运 
磷虾和/或海产油作为一种皮肤病局部治疗用途的基质增强透皮转运。它可以通过乳膏、软膏、凝胶、洗液和油而用于皮肤病治疗。它还可以用于多种治疗用途,例如关于麻醉、皮质类固醇、抗炎、抗生素和酮解功能的治疗用途。 
为了评价磷虾和/或海产油作为局部治疗的基质的效力和磷虾和/或海产单独或作为一种基质的透皮吸收的速度,对C57BL6裸同类素小鼠-B6NU-T(杂合体)进行随机的盲对照试验研究。 
结果出现在表5和6中,它表明用磷虾油局部治疗促进视黄醇和其它抗氧剂的透皮吸收,从而导致显著的光保护潜力,并进而导致100%的对UVB诱导的皮肤癌的保护作用。相反,鱼油和全反式视黄醇的用途导致癌发生率为68.8%。 
实施例5
皮肤病局部润肤应用的透皮转运 
磷虾和/或海产油作为一种基质可以用于增强皮肤病局部润肤应用的透皮转运,其中润肤应用涉及皮肤水合、抗皱、角质层分离剂、去皮和通过乳膏、软膏、凝胶、洗液或油化装。 
为了评价磷虾和/或海产油在衰老和面部皱纹的作用,对涉及面部干燥和皱纹的患者进行前瞻性临床试验研究。这些患者无严重其它限于皮肤病或非皮肤病症状、出血倾向或严重精神病的预后症状。 
已将13名患有面部干燥和皱纹的健康高加索妇女纳入本研究。要求妇女服入6个胶囊/天,每个胶囊包含800mg磷虾提取物。建议的日剂量为大约1-4.8g磷虾提取物。 
表9表明根据前述的方法进行皮肤水合时所得的结果。 
表9 
皮肤水合的变化 
    频率%   %   有效%   蓄积%
  无变化   4   30.8   30.8   30.8
  水合   9   69.2   69.2   100.0
  总数   13   100.0   100.0  
2个月后的小规模研究的结果表明13分之9(69.2%)的人报道明显改善人患者皮肤(面部、手和手臂)的水合、纹理和弹性。 
而且,这些结果还表明磷虾提取物用于抗皱治疗。磷虾油中包含的全反式视黄醇作为抗皱剂的工作机理如下: 
-再生作用和明显的抗炎作用 
-改善血液灌注 
-通过增加细胞分化和更新速率而增加表皮再生 
-加速角蛋白分化 
-再生胶原 
-使总被替换的皮肤上层细胞比未治疗的阳光破坏的细包更为正常地成熟 
-减少分解提供皮肤结构载体的蛋白胶原和弹性蛋白的酶的活化。 
给患者皮肤施用磷虾提取物得到的结果表明磷虾提取通过增加水合和上述的机理而具有抗皱作用。 
实施例6
经前综合症 
表10表示使用磷虾油降低疼痛和与妇女经前综合症有关的心情变化得到的结果。在2个月期间给7名妇女施用磷虾油提取物。妇女每天服用6个胶囊的磷虾提取物,每个胶囊包含800mg磷虾油。建议的日摄入磷虾油为大约1-4.8克。建议所有的参加者继续他们平常的营养习惯,并抑制开始对它们的饮食进行任何限制。没有报道严重的副作用。 
所有登记的妇女报道在月经前7-10天有明显的情绪和/或身体不适。一个用于对经前综合症的评价进行验证,范围为0(无症状)至10(无法忍受)自我评价的视觉类似物数值范围用作基本结果,以评价磷虾提取物对经前不适的作用。 
已报道了60%的参加研究并已完成2个月治疗方案的妇女的数据分析。大部分的妇女(73.3%)在临床上表现出月经前情绪和身体压力的显著减少(参见表10)。 
表10 
磷虾提取物对经前综合症的症状的作用的频率分布 
  PMS症状   频率%   有效%   蓄积%
  无变化   26.7   26.7   26.7
  阳性   73.3   73.3   100.0
  总数   100.   100.0  
实施例7
糖尿病 
在2个月期间8名患者以6个胶囊/天的剂量服用磷虾提取物,每个胶囊包含800mg磷虾提取物。建议的日摄入磷虾油为大约1-4.8克。 
表11表明测定患者在2个月之后的葡萄糖变化。 
表11
患者葡萄糖的变化 
服用磷虾提取物的患者的血糖降低20%,这表明磷虾提取物的摄入控制血糖含量,从而控制人患者的糖尿病。 
虽然已联系特定的实施方案描述本发明,但应理解可以进行进一步修改,且这种用途意在覆盖根据本发明的一般原则对本发明进行的任何改型、用途或修改,并包括在本发明所属技术的已知或常规实践中产生,可以适用于本文上述的必要特征,并遵循所附的权利要求的范围的本发明内容的背离。 

Claims (55)

1.不含酶的多治疗磷虾油提取物在生产用于降低患者胆固醇的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
2.如权利要求1所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
3.如权利要求2所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
4.如权利要求3所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
5.如权利要求1所述的用途,其中将所述药物配制成口服给药制剂。
6.不含酶的多治疗磷虾油提取物在生产用于预防患者高血压的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
7.如权利要求6所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
8.如权利要求6所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
9.如权利要求8所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
10.如权利要求6所述的用途,其中将所述药物配制成口服给药制剂。
11.不含酶的多治疗磷虾油提取物在生产用于控制患者血糖水平的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
12.如权利要求11所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
13.如权利要求12所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
14.如权利要求13所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
15.如权利要求11所述的用途,其中将所述药物配制成口服给药制剂。
16.不含酶的多治疗磷虾油提取物在生产用于在患者中症状控制或治疗关节炎的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
17.如权利要求16所述的用途,其中所述关节炎选自风湿性关节炎和骨关节炎。
18.如权利要求17所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
19.如权利要求18所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
20.如权利要求19所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
21.如权利要求16所述的用途,其中将所述药物配制成口服给药制剂。
22.不含酶的多治疗磷虾油提取物在生产用于预防患者皮肤癌的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
23.如权利要求22所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
24.如权利要求31所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
25.如权利要求24所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
26.如权利要求22所述的用途,其中将所述药物配制成口服和/或局部给药制剂。
27.不含酶的多治疗磷虾油提取物在生产用于在患者中增强皮肤病学化妆品应用领域的透皮转运的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
28.如权利要求27所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
29.如权利要求38所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
30.如权利要求29所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
31.如权利要求27所述的用途,其中将所述药物配制成口服和/或局部给药制剂。
32.不含酶的多治疗磷虾油提取物在生产用于减少患者经前综合症症状的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
33.如权利要求32所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
34.如权利要求33所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
35.如权利要求34所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
36.如权利要求32所述的用途,其中将所述药物配制成口服给药制剂。
37.不含酶的多治疗磷虾油提取物在生产用于减少患者血小板粘附和斑块形成的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
38.如权利要求37所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
39.如权利要求38所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
40.如权利要求39所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
41.如权利要求37所述的用途,其中将所述药物配制成口服给药制剂。
42.不含酶的多治疗磷虾油提取物在生产用于降低患者血管内皮炎症或关节炎的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
43.如权利要求42所述的用途,其中所述炎症是血管内皮细胞炎症。
44.如权利要求43所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
45.如权利要求60所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮。
46.如权利要求45所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
47.如权利要求42所述的用途,其中将所述药物配制成口服给药制剂。
48.不含酶的多治疗磷虾油提取物在生产用于在患者中升高HDL的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
49.不含酶的多治疗磷虾油提取物在生产用于在患者中升高HDL和降低LDL和甘油三酸酯的药物中的用途,其中所述磷虾油提取物的过氧化物值<0.1(mEq/kg),并且其中所述磷虾油提取物含有至少4.5g/100g的磷脂酰胆碱和不超过55g/100g的甘油三酸酯。
50.如权利要求48或49所述的用途,其中所述磷虾油提取物来自于至少一种海产材料。
51.如权利要求50所述的用途,其中所述磷虾油提取物包括二十碳五烯酸、二十二碳六烯酸、磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺、鞘磷脂、α-生育酚、全反式视黄醇、虾青素和类黄酮,磷脂和抗氧化剂。
52.如权利要求51所述的用途,其中所述磷脂选自磷脂酰胆碱、磷脂酰肌醇、磷脂酰丝氨酸、磷脂酰乙醇胺和鞘磷脂中的至少一种。
53.如权利要求51所述的用途,其中所述抗氧化剂选自α-生育酚、虾青素和类黄酮中的至少一种。
54.如权利要求51所述的用途,其中所述磷虾油提取物还包括至少一种选自以下的成分:亚油酸、α-亚油酸、花生四烯酸、油酸、棕榈酸、棕榈油酸、硬脂酸、胆固醇、甘油三酸酯、甘油一酸酯、全反式视黄醇、斑蝥黄、β-胡萝卜素、锌、硒、神经酸、钠、钾和钙。
55.如权利要求48或49所述的用途,其中将所述药物配制成口服给药制剂。
CN201110219831.4A 2001-06-18 2002-06-07 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物 Expired - Lifetime CN102319266B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29838301P 2001-06-18 2001-06-18
US60/298,383 2001-06-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA028121813A Division CN1516592A (zh) 2001-06-18 2002-06-07 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物

Publications (2)

Publication Number Publication Date
CN102319266A CN102319266A (zh) 2012-01-18
CN102319266B true CN102319266B (zh) 2014-12-17

Family

ID=23150259

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201110219831.4A Expired - Lifetime CN102319266B (zh) 2001-06-18 2002-06-07 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
CNA028121813A Pending CN1516592A (zh) 2001-06-18 2002-06-07 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028121813A Pending CN1516592A (zh) 2001-06-18 2002-06-07 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物

Country Status (14)

Country Link
US (5) US20040241249A1 (zh)
EP (2) EP1406641B1 (zh)
JP (4) JP5135568B2 (zh)
CN (2) CN102319266B (zh)
AT (2) ATE419858T1 (zh)
CA (1) CA2449898C (zh)
CY (1) CY1108986T1 (zh)
DE (1) DE60230759D1 (zh)
DK (2) DK1997498T3 (zh)
ES (2) ES2386841T3 (zh)
HK (2) HK1126957A1 (zh)
NO (1) NO332690B1 (zh)
PT (1) PT1406641E (zh)
WO (1) WO2002102394A2 (zh)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011873A2 (en) 2001-07-27 2003-02-13 Neptune Technologies & Bioressources Inc. Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
AU2013205515B2 (en) * 2001-07-27 2015-07-02 Aker Biomarine Antarctic As Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
ATE427106T1 (de) * 2003-01-20 2009-04-15 Tno Die verwendung von sphingolipiden zur senkung der cholesterin- und triglyzeridspiegel im plasma.
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
GB0314624D0 (en) 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
FR2859380B1 (fr) * 2003-09-05 2006-02-10 Phythea Composition destinee au traitement cosmetique de la peau d'un etre humain
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
AU2004287440A1 (en) 2003-10-28 2005-05-19 Emory University Dialysates and methods and systems related thereto
JP4522075B2 (ja) * 2003-10-29 2010-08-11 サントリーホールディングス株式会社 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物
CA2555281C (en) * 2004-02-06 2012-11-13 Adrien Beaudoin Method for preventing the oxidation of lipids in animal and vegetable oils and compositions used by the method
JP5154218B2 (ja) * 2004-03-16 2013-02-27 ネーデルランドセ オルガニサティエ フォール トエゲパスト−ナトールヴェテンシャッペリク オンデルゾエク ティエヌオー 2型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
ATE539741T1 (de) 2004-11-30 2012-01-15 Tno Sphingolipide bei der behandlung und prävention von hepatischer steatose
JP2006016408A (ja) * 2005-06-23 2006-01-19 Yamaha Motor Co Ltd 血中中性脂肪抑制剤
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および/又はうつ症状の改善作用を有する組成物
EP1951071A2 (en) * 2005-10-18 2008-08-06 Artmed S.r.l. Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma
AR059012A1 (es) * 2006-01-13 2008-03-05 Aker Biomarine Asa Extractos derivados del krill
US20070213298A1 (en) * 2006-02-07 2007-09-13 Universitetet I Oslo Omega 3
PL2046312T3 (pl) * 2006-07-14 2021-02-08 Kaydence Pharma As Produkty farmaceutyczne i nutraceutyki zawierające witaminę K2
BRPI0718393A2 (pt) * 2006-11-03 2013-11-26 Pronova Biopharma Norge As Álcoois de ácido graxo
EP3593797A1 (en) 2006-12-28 2020-01-15 Suntory Holdings Limited Nerve-regenerating agent
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
AU2011213836B2 (en) * 2007-03-28 2013-11-14 Aker Biomarine Antarctic As Bioeffective krill oil compositions
ES2415684T3 (es) 2007-03-28 2013-07-26 Aker Biomarine As Composiciones de aceite de kril biológicamente eficaces
AU2014100740B4 (en) * 2007-03-28 2014-11-20 Aker Biomarine Antarctic As Processes and products thereof
KR101343290B1 (ko) * 2007-08-29 2013-12-18 에이커 바이오마린 에이에스 새로운 크릴 밀 제조 방법
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
AU2014100741B4 (en) * 2007-08-29 2014-09-11 Aker Biomarine Antarctic As Processes and products thereof
AU2012244229B2 (en) * 2007-08-29 2013-11-21 Aker Biomarine Antarctic As A new method for making krill meal
US8911888B2 (en) 2007-12-16 2014-12-16 HGST Netherlands B.V. Three-dimensional magnetic memory with multi-layer data storage layers
US8586104B2 (en) * 2008-04-10 2013-11-19 U.S. Nutraceuticals, LLC Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use
US8829215B2 (en) * 2008-05-15 2014-09-09 Pronova Biopharma Norge As Krill oil process
US9239334B2 (en) * 2008-09-08 2016-01-19 President And Fellows Of Harvard College Fatty acid C16: 1N7-palmitoleate a lipokine and biomarker for metabolic status
EP3238551B1 (en) 2008-09-12 2019-11-27 Rimfrost Technologies AS Process for reducing the fluoride content when producing proteinaceous concentrates from krill
US8557297B2 (en) 2008-09-12 2013-10-15 Olympic Seafood, As Method for processing crustaceans and products thereof
US9814256B2 (en) 2009-09-14 2017-11-14 Rimfrost Technologies As Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof
KR101024491B1 (ko) * 2008-12-31 2011-03-31 인성실업(주) 해양 동물로부터 지질을 추출하는 방법
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
JP2010241710A (ja) * 2009-04-02 2010-10-28 Japan Health Science Foundation Ace2活性誘導剤
US9925162B2 (en) 2009-04-09 2018-03-27 The Regents Of The University Of Colorado Methods and compositions for inducing physiological hypertrophy
WO2010136900A2 (en) 2009-05-28 2010-12-02 Aker Biomarine Asa Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders
US9399047B2 (en) 2009-07-23 2016-07-26 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and roe extract
US8481072B2 (en) 2009-07-23 2013-07-09 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain
US9913810B2 (en) 2009-07-23 2018-03-13 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using phospholipids and astaxanthin
US8557275B2 (en) 2009-07-23 2013-10-15 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US20130295171A1 (en) 2009-07-23 2013-11-07 U.S NUTRACEUTICALS, LLC d/b/a Valensa International Krill oil and reacted astaxanthin composition and associated method
US9216164B2 (en) 2009-07-23 2015-12-22 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
US9238043B2 (en) 2009-07-23 2016-01-19 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using algae based oils
US9402857B2 (en) 2009-07-23 2016-08-02 U.S. Nutraceuticals, LLC Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
US8586567B2 (en) 2009-10-29 2013-11-19 Acasti Pharma, Inc. Concentrated therapeutic phospholipid compositions
KR101616446B1 (ko) 2009-10-30 2016-04-28 샤로스 리미티드 인지질과 중성 지질이 풍부한 크릴 오일을 용매를 사용하지 않고 생산하는 방법
WO2011060170A1 (en) * 2009-11-11 2011-05-19 Dynasep Llc Energy efficient acetone drying method
US20110117207A1 (en) * 2009-11-17 2011-05-19 U.S. Nutraceuticals, LLC d/b/a Valensa International State of Incorporation: Use of eggshell membrane formulations to alleviate joint pain
WO2011137160A2 (en) 2010-04-30 2011-11-03 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans
US9763897B2 (en) 2010-04-30 2017-09-19 U.S. Nutraceuticals, LLC Therapeutic astaxanthin and phospholipid composition and associated method
US8663704B2 (en) 2010-04-30 2014-03-04 U.S. Nutraceuticals, LLC Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
US8691297B2 (en) 2010-09-01 2014-04-08 Nippon Suisan Kaisha, Ltd. Alcoholic injury mitigating agent
KR20120051458A (ko) * 2010-11-12 2012-05-22 주식회사 두산 크릴 인지질을 이용하여 아스타잔틴 및 dha- 및/또는 epa-결합된 포스파티딜세린을 함유한 조성물을 제조하는 방법 및 이러한 방법에 의해 제조된 조성물
CN102485899A (zh) * 2010-12-03 2012-06-06 张永志 一种制备富含多不饱和双键脂肪酰基的磷脂酰丝氨酸的高品质南极磷虾油的方法
CN102041166B (zh) * 2011-01-20 2012-05-23 山东师范大学 从南极磷虾中提取高磷脂含量的虾油的方法
WO2012103685A1 (en) * 2011-02-01 2012-08-09 Nippon Suisan Kaisha, Ltd. Sexual function improving agent
KR101045258B1 (ko) * 2011-02-11 2011-06-30 대덕에프알디(주) 크릴 오일 제조 방법 및 상기 방법에 의해 제조된 크릴 오일
US20120231087A1 (en) * 2011-03-07 2012-09-13 Olympic Seafood Compositions And Methods for Nutritional Supplementation
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
HUE036720T2 (hu) * 2011-06-15 2018-07-30 Stable Solutions Llc Parenterális krill olaj terápiás alkalmazása
BR112013032410A2 (pt) * 2011-06-24 2017-01-17 Epitogenesis Inc composições farmacêuticas compreendendo uma combinação de veículos, vitaminas, taninos e flavonoides de seleção como imunomoduladores específicos de antígeno
US9107891B2 (en) 2011-06-29 2015-08-18 Nippon Suisan Kaisha, Ltd. Method for alleviating fear memory
WO2013033618A1 (en) 2011-09-02 2013-03-07 Arctic Nutrition As Lipid compositions with high dha content
RU2664429C2 (ru) 2012-01-06 2018-08-17 Омтера Фармасьютикалс, Инк. Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA
CN102559371B (zh) * 2012-02-21 2013-09-18 山东师范大学 一种制备富含磷脂酰丝氨酸的虾油的方法
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
EP3591103A1 (en) 2012-09-07 2020-01-08 Japan Science and Technology Agency Guest-compound-enveloping polymer-metal-complex crystal, method for producing same, method for preparing crystal structure analysis sample, and method for determining molecular structure of organic compound
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
CN102899162B (zh) * 2012-10-25 2013-12-04 山东师范大学 一种制备低氟含量的南极磷虾虾油的工艺
CN102899164B (zh) * 2012-10-25 2015-12-02 山东师范大学 一种制备无氟南极磷虾虾油的工艺
CN102925284B (zh) * 2012-10-25 2014-01-08 山东师范大学 一种从南极磷虾中提取低胆固醇含量的虾油的工艺
CN102911786B (zh) * 2012-10-25 2014-01-08 山东师范大学 一种从南极磷虾中提取低氟含量的虾油的工艺
CN102899163B (zh) * 2012-10-25 2015-03-25 山东师范大学 一种从南极磷虾中提取无氟虾油的工艺
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
WO2014184655A1 (en) 2013-02-07 2014-11-20 Olympic Seafood As Methods for using crustacean phospholipid-peptide-protein complexes
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
JP6393501B2 (ja) * 2014-04-03 2018-09-19 太陽化学株式会社 多価不飽和脂肪酸含有油脂の風味改善剤
US11382980B2 (en) 2013-10-08 2022-07-12 Taiyo Kagaku Co., Ltd. Oil/fat composition containing polyunsaturated fatty acid
JP2015096488A (ja) * 2013-10-10 2015-05-21 康二 嘉島 終末糖化物質生成抑制方法
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
WO2015142702A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and roe extract
WO2015142707A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin
WO2015142700A1 (en) 2014-03-18 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using phospholipids and astaxanthin
WO2015142999A1 (en) 2014-03-19 2015-09-24 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin
AU2015265623A1 (en) * 2014-04-30 2016-11-10 Aker Biomarine Antarctic As Krill oil preparations and their uses
JP6299689B2 (ja) * 2014-07-24 2018-03-28 三生医薬株式会社 生体吸収促進剤含有組成物
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
NZ735362A (en) 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions
EP3256003B1 (en) 2015-02-11 2022-11-09 Aker Biomarine Antarctic AS Lipid extraction processes
US10328105B2 (en) 2015-05-27 2019-06-25 Rimfrost Technologies As Flowable concentrated phospholipid krill oil composition
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
CN105341184A (zh) * 2015-10-14 2016-02-24 中国农业科学院油料作物研究所 一种具有预防心脑血管疾病和糖尿病风险因子作用的功能性油脂组合物
EP4233855A3 (en) * 2015-12-14 2024-01-17 Société des Produits Nestlé S.A. Nutritional composition and infant formula for promoting myelination of the brain
DE202015106826U1 (de) * 2015-12-15 2016-02-03 Wolfgang Braun Zusammensetzung zur Behandlung von Prämenstruellem Syndrom
BR112018077350A2 (pt) 2016-06-29 2019-04-09 Machavert Pharmaceuticals Llc composições de fosfolipídio
WO2018083271A1 (en) * 2016-11-04 2018-05-11 Immd Sp. Zo.O Inteligent delivery of ingested and absorbed molecules
JP7309136B2 (ja) * 2017-04-14 2023-07-18 学校法人帝京大学 Hdl機能改善剤及びhdl機能改善食品組成物
EP3727404B1 (en) 2017-12-22 2023-08-30 Pharmalink International Limited Compositions comprising mussel lipid extract and krill oil, and their medical applications
WO2019226186A1 (en) 2018-05-24 2019-11-28 U.S. Nutraceuticals, Llc D/B/A Valensa International Composition and method to alleviate joint pain using hyaluronic acid and eggshell membrane components
JP2019210239A (ja) * 2018-06-02 2019-12-12 学校法人 岩手医科大学 8−ヒドロキシエイコサペンタエン酸の薬理用途
DE202018105422U1 (de) 2018-06-21 2018-10-19 U.S. Nutraceuticals, Llc D/B/A Valensa International Zusammensetzung zur Linderung von Gelenkschmerzen unter Verwendung von Hyaluronsäure und Eierschalenmembrankomponenten
CA3110779A1 (en) * 2018-06-28 2020-01-02 Michael K. HANDLEY Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
US20220265291A9 (en) * 2018-06-28 2022-08-25 Marizyme, Inc. Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices
KR102085506B1 (ko) * 2018-07-25 2020-03-05 이경희 두피자극완화용 염모제 첨가조성물 및 두피자극완화용 염모제
WO2021138742A1 (en) * 2020-01-10 2021-07-15 Acasti Pharma Inc. Composition that promote pro-resolving mediators
IT202000003964A1 (it) * 2020-02-26 2021-08-26 Umberto Cornelli Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale
KR102451162B1 (ko) * 2020-09-07 2022-10-06 (주)에스디생명공학 효소처리 크릴 오일 추출물을 유효성분으로 포함하는 항염증, 피부 주름개선, 보습 및 피부 재생 촉진용 조성물
CN112315984B (zh) * 2020-09-09 2023-02-14 山东省科学院生物研究所 海洋来源磷脂在促进血管生成方面的应用
CN112494499B (zh) * 2020-12-14 2022-01-28 山东省科学院生物研究所 海洋磷脂作为有效成分在制备预防和/或治疗心脏疾病药物中的应用
AU2022224703A1 (en) * 2021-09-28 2023-04-13 Samuel L. Shepherd Tetraterpenes for use in cancer therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54119017A (en) * 1978-03-06 1979-09-14 Taiyo Fishery Co Ltd Protective agent for hypertensive disease and production
JPS60153779A (ja) 1984-01-24 1985-08-13 Hohnen Oil Co Ltd 栄養補助食品
JPS6130527A (ja) * 1984-07-20 1986-02-12 Kao Corp 血栓溶解剤
JPS61118318A (ja) * 1984-11-12 1986-06-05 Pola Chem Ind Inc 血清脂質改善用組成物
JPS63295698A (ja) * 1987-05-27 1988-12-02 Showa Denko Kk α−リノレン酸の分離精製法
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
JPH01137952A (ja) * 1987-11-20 1989-05-30 Nippon Suisan Kaisha Ltd 健康食品
JPH02167055A (ja) * 1988-12-19 1990-06-27 Seiji Nojima 機能性練製品
JPH03123470A (ja) * 1989-10-05 1991-05-27 Taiyo Fishery Co Ltd オキアミ中のアンジオテンシン変換酵素阻害活性の増強法
JP2558050B2 (ja) * 1993-02-18 1996-11-27 イセ食品株式会社 鶏用飼料
JPH08219A (ja) * 1994-06-15 1996-01-09 Nippon Synthetic Chem Ind Co Ltd:The 機能の改善された油組成物
JP2666179B2 (ja) * 1994-08-10 1997-10-22 財団法人韓國食品開發研究院 抗高血圧健康食品組成物
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
JP3664814B2 (ja) * 1996-06-26 2005-06-29 旭化成ケミカルズ株式会社 血中脂質改善剤及び食品添加剤
JP3118556B2 (ja) * 1996-09-27 2000-12-18 中央水産研究所長 魚肉水溶性タンパク質により油脂を高濃度に含有させた魚肉乳化すり身及びその製造法
CA2251265A1 (en) * 1998-10-21 2000-04-21 Universite De Sherbrooke Process for lipid extraction of aquatic animal tissues producing a dehydrated residue

Also Published As

Publication number Publication date
HK1126957A1 (en) 2009-09-18
EP1997498B1 (en) 2012-04-25
DE60230759D1 (de) 2009-02-26
US20070098808A1 (en) 2007-05-03
NO20035618D0 (no) 2003-12-16
JP5135568B2 (ja) 2013-02-06
US20110305771A1 (en) 2011-12-15
US8057825B2 (en) 2011-11-15
EP1406641A2 (en) 2004-04-14
US20170224742A1 (en) 2017-08-10
JP2013079278A (ja) 2013-05-02
ATE554779T1 (de) 2012-05-15
PT1406641E (pt) 2009-04-15
CN102319266A (zh) 2012-01-18
CY1108986T1 (el) 2014-07-02
CA2449898A1 (en) 2002-12-27
NO332690B1 (no) 2012-12-10
ES2321066T3 (es) 2009-06-02
US20040241249A1 (en) 2004-12-02
WO2002102394A3 (en) 2003-04-10
HK1165729A1 (zh) 2012-10-12
US20140199414A1 (en) 2014-07-17
CA2449898C (en) 2018-03-06
CN1516592A (zh) 2004-07-28
DK1997498T3 (da) 2012-07-30
JP2004534800A (ja) 2004-11-18
EP1997498A3 (en) 2009-06-03
JP2010090141A (ja) 2010-04-22
JP2010090140A (ja) 2010-04-22
ATE419858T1 (de) 2009-01-15
DK1406641T3 (da) 2009-05-04
JP5228185B2 (ja) 2013-07-03
EP1997498A2 (en) 2008-12-03
EP1406641B1 (en) 2009-01-07
ES2386841T3 (es) 2012-09-03
WO2002102394A2 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
CN102319266B (zh) 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
EP1337263B1 (en) A composition of rose hip and fish oil for alleviating joint pain and stiffness
JP3008213B2 (ja) 医薬組成物
US7666447B2 (en) Compositions including Krill extracts and conjugated linoleic acid and methods of using same
Takahashi et al. Reduction in formation and growth of 1, 2-dimethylhydrazine-induced aberrant crypt foci in rat colon by docosahexanoic acid
EP1871399B1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
Badiu et al. Effect of olive oil on the skin
JP4820819B2 (ja) 過剰増殖性皮膚疾患を治療するための組成物および方法
CA2024724A1 (en) Fatty acid therapy
Šunderić et al. Is there something fishy about fish oil?
EP0238198A2 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
HODGES Vitamin Eand
Belluzzi 16 Polyunsaturated Fatty Acids
Lieberman Natural Interventions for Treating Psoriasis
US20160106723A1 (en) Methods to sense and treat subclinical skin damage
WO2011070568A1 (en) Method for treating psoriasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1165729

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1165729

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20141217